Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Mallinckrodt
Novartis
Covington
Citi
Johnson and Johnson
Medtronic
Cipla
Fuji
Federal Trade Commission

Generated: August 22, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022426

« Back to Dashboard
NDA 022426 describes OSENI, which is a drug marketed by Takeda Pharms Usa and is included in one NDA. It is available from two suppliers. There are ten patents protecting this drug. Additional details are available on the OSENI profile page.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. There are nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

Summary for NDA: 022426

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:10
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 022426

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
OSENI
alogliptin benzoate; pioglitazone hydrochloride
TABLET;ORAL 022426 NDA AUTHORIZED GENERIC Perrigo New York Inc 45802-238 45802-238-65 30 TABLET, FILM COATED in 1 BOTTLE (45802-238-65)
OSENI
alogliptin benzoate; pioglitazone hydrochloride
TABLET;ORAL 022426 NDA AUTHORIZED GENERIC Perrigo New York Inc 45802-260 45802-260-65 30 TABLET, FILM COATED in 1 BOTTLE (45802-260-65)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 25MG BASE;EQ 15MG BASE
Approval Date:Jan 25, 2013TE:RLD:Yes
Patent:► SubscribePatent Expiration:Mar 15, 2025Product Flag?Substance Flag?YDelist Request?
Patent:► SubscribePatent Expiration:Jun 4, 2029Product Flag?YSubstance Flag?Delist Request?
Regulatory Exclusivity Expiration:Apr 5, 2019
Regulatory Exclusivity Use:INFORMATION ADDED TO THE LABELING DESCRIBING EXAMINE, A TRIAL EVALUATING CARDIOVASCULAR ISCHEMIC RISKS ASSOCIATED WITH ALOGLIPTIN USE IN PATIENTS WITH TYPE 2 DIABETES AT HIGH RISK OF ISCHEMIC CARDIOVASCULAR DISEASE

Expired Orange Book Patents for NDA: 022426



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Boehringer Ingelheim
Harvard Business School
Merck
Deloitte
Dow
Johnson and Johnson
Chinese Patent Office
US Army
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot